Reimbursed Care Access in Micronesia

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. FSM’s controlled‑substances schedules explicitly list psilocybin/psilocyn as controlled substances. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. FSM’s controlled‑substances framework follows the Trust Territory / U.S. model and treats MDMA as an illicit controlled drug; no national medical/insured access pathway for MDMA-assisted therapy is present in FSM statutory materials. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no indication in FSM statutory materials or government listings that the proprietary nasal esketamine product (marketed elsewhere for TRD) has a national regulatory approval or a reimbursed, nationally sanctioned treatment pathway in FSM. FSM regulates controlled substances under Title 11; any importation/clinical use would need to comply with FSM scheduling and import controls. #.

Ketamine is not treated in FSM as an uncontrolled ‘recreational-only’ compound insofar as the FSM controlled‑substances regime governs importation, distribution and clinical dispensing of controlled medicines; injectable ketamine is widely recognized on the World Health Organization Model List of Essential Medicines for use as an anaesthetic and for emergency medicine and therefore may be legally supplied and used in clinical settings subject to FSM regulatory controls and practitioner licensing. #; FSM controlled‑substances law establishes schedules, registration and penalties that govern manufacture, import and medical dispensing and therefore ketamine use in FSM occurs under those medical/regulatory controls (Title 11, Chapter 11 of the FSM Code). #.

Clinical and reimbursement context: FSM does not publish a publicly available national pharmacare list or national reimbursement program analogous to large-country public health insurance schemes for novel psychiatric indications; ketamine’s established uses (general anaesthesia, procedural sedation, emergency analgesia) would be provided through licensed clinical services in hospitals or clinics and procured under the FSM importation/medical supply rules rather than through a separate psychedelic‑therapy reimbursement pathway. Any use of ketamine for off‑label psychiatric indications (e.g., infusional ketamine for depression) would therefore be institutionally determined, require appropriate practitioner oversight and import/dispensing compliance with FSM controlled‑substance regulations; there is no evidence of an FSM‑wide, publicly reimbursed ketamine‑for‑psychiatric‑disorders program in statutory materials. #; #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. FSM’s schedules and the international scheduling of DMT place it under strict control; there is no national medical access pathway in FSM statutory materials. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. FSM law lists broad tryptamine/psychedelic categories and includes related substances; 5‑MeO‑DMT has no recognized medical access pathway in FSM. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. FSM specifically enumerates ibogaine among controlled substances in its schedules; there is no authorized domestic medical or reimbursement framework for ibogaine. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While 'ayahuasca' as a botanical decoction is not separately enumerated in many codes, FSM’s scheduling controls the principal psychoactive constituent (DMT) and broad manufacturing/import/possession prohibitions apply; there is no authorized traditional‑use or medical exemption published in FSM statutory materials. #; #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. FSM’s schedules explicitly list mescaline and peyote as controlled substances; no authorized medical or reimbursed therapeutic pathway for mescaline exists in FSM law. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Phenethylamine derivatives and 'designer' amphetamines/phenethylamines are encompassed by FSM controlled‑substance provisions; there is no medical/reimbursement access for 2C‑series compounds in FSM. #.